This trial is active, not recruiting.

Condition human t-cell leukemia virus type 1 infection
Treatment raltegravir
Phase phase 2
Sponsor Washington University School of Medicine
Collaborator Merck Sharp & Dohme Corp.
Start date January 2012
End date December 2013
Trial size 14 participants
Trial identifier NCT01620736, WashU201109171


This is a study of the effect of raltegravir on human T-cell leukemia virus type 1 (HTLV-1) viral load in asymptomatic patients. The study will enroll 14 subjects for a period of 2 months of treatment and 1 month of followup. The study will assess the effect of raltegravir on virus load in peripheral blood lymphocytes, level of virus gene expression, and sites of viral integration.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Treatment with raltegravir for 8 wks
Raltegravir 400 mg po bid

Primary Outcomes

Effects of raltegravir on HTLV-1 provirus load in asymptomatic individuals
time frame: 8 wks

Secondary Outcomes

Effects of raltegravir on proviral load in CD4+CD25+, CD4+CD25-, and CD8+ cell populations
time frame: 8 wks
Effects of raltegravir on number of LTR circles and level of proviral RNA expression in PBMCs
time frame: 8 wks
Effects of raltegravir on viral integrase gene or other viral sequence changes
time frame: 8 wks
Effect of raltegravir on viral integration sites
time frame: 8 wks
Tolerance of raltegravir in HTLV-1 infected individuals
time frame: 8 wks

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Documented HTLV-1 infection: documentation may be serologic assay (ELISA, Western blot) and confirmed to be HTLV-1 rather than HTLV-2 by differential Western blot (e.g. Genelabs Diagnostics HTLV Blot 2.4) or PCR. 2. Adequate hematologic function within 14 days before enrollment: ANC > 1000 cells/mm3, platelet count > 75,000 cells/mm3. 3. Adequate hepatic function, transaminase < 3 times the upper limit of normal; bilirubin < 2.0. 4. Creatinine < 2.0 5. Karnofsky Performance Status at least 70 6. Age at least 18. 7. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. 8. Female patients of child bearing potential must have a negative pregnancy test within 72 hrs of initiation of therapy. Female patients are either post-menopausal or surgically sterilized or willing to use two acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) during the study. Male patients must agree to use two acceptable methods for contraception for the duration of the study. Women must avoid pregnancy and men avoid fathering children while in the study. 9. Inclusion of Women and Minorities: Both men and women and members of all races and ethnic groups are eligible for this trial. Exclusion Criteria: 1. Acute active infection requiring therapy. Chronic therapy with potentially myelosuppressive agents is allowed provided that entry hematologic criteria are met. 2. Women who are pregnant or breastfeeding. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. 3. Patient has received other investigational drugs with 14 days before enrollment 4. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

Additional Information

Official title Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load
Principal investigator Lee Ratner, MD PhD
Description About 5% of HTLV-1 infected individuals develop lymphoma or myelopathy. High levels of virus replication are predictive of disease development. HTLV-1 exhibits lower levels of variation than HIV-1, suggesting that drug resistance is less likely to occur. Raltegravir was shown to inhibit HTLV-1 integration and replication in culture using concentrations achievable with the approved dose used in HIV-1 infected patients. Currently, no treatment is recommended for asymptomatic infected individuals.
Trial information was received from ClinicalTrials.gov and was last updated in June 2012.
Information provided to ClinicalTrials.gov by Washington University School of Medicine.